Growing epidemiological evidence indicates that inflammation may play an important role in cancer. Aspirin andother NSAIDs share an ability to reduce inflammatory responses by inhibiting the synthesis of prostaglandins from arachidonic acid. Our study revealed that aspirin appeared
to be a protective factor of stomach cancer. Moreover, we presented that higher dosage and longer tablet year use reduced the risk. Finally, the result was strengthened by stratified analysis of gender, smoking status, BMI degree and helicobacter pylori infection. Our study stands in line with several studies. Gridley G et al.13 discovered that a decreased risk of stomach cancer was noted among patients with rheumatoid arthritis who regular used aspirin (standardized incidence ratios (SIR) 0.63; 95% CI ผ 0.5e0.9)). Later Zaridze D et al.,14 confirmed that aspirin use was associated with protection against stomach cancer (OR ผ 0.60, 95% CI 0.41e0.90). However, other studies presented the null association. Schreinemachers DM and Everson RB15 indicated no significant relationship was observed based on data from the National Health and Nutrition Examination Survey I (NHANES I) and the NHANES I Epidemiologic Follow-up Studies (NHEFS). Farrow DC et al.16 completed a large population-based caseecontrol study identified 261 cases of stomach cancer, and founded that OR of 0.80 (95%CI, 0.54e1.19) for gastric cardia adenocarcinoma among regular users of aspirin, compared to never-users.